이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease

SPECT Evaluation of Nicotinic Cholinergic Receptors in Parkinson's Disease

This study will use single photon emission computed tomography, or SPECT (see below), to examine brain nicotine receptors in evaluating the role of a chemical called acetylcholine in memory and other problems in Parkinson's disease (PD). Acetylcholine acts by binding to these nicotine receptors.

Healthy normal volunteers and patients with Parkinson's disease 40 years of age and older, with or without dementia, may be eligible for this study. Candidates will be screened with physical and neurological examinations, a pen and paper test of memory and other mental functions, blood tests, and, for women of childbearing potential, a pregnancy test. Patients with cognition problems will have more intensive mental function tests.

All participants will undergo the following procedures:

  • Magnetic resonance imaging (MRI): This test uses a strong magnetic field and radio waves to show structural and chemical changes in the brain. During the scan, the subject lies on a table in a narrow cylinder (the scanner). The time required in the scanner is about 1 hour, during which the subject is asked to lie very still for 10 to 15 minutes at a time. He or she can speak with a staff member via an intercom system at all times during the procedure.
  • SPECT: This nuclear medicine test produces a picture of the receptors in the brain. On the night before the scan, the day of the scan, and for 4 days after the scan, subjects take an oral dose of potassium iodide to protect the thyroid gland from the radioactive tracer used in the SPECT procedure. (People allergic to potassium iodide will take potassium perchlorate instead.) Before the scan, small radioactive markers containing 99Tc are glued to the subject's head. Two catheters (thin, flexible tubes) are placed in veins in the arms to inject the radioactive tracer [123I]5-I-A-85380 and to draw blood samples. Another catheter is placed in an artery in the wrist to draw arterial blood samples. During the scan, the subject lies on a bed with his or her head held still with a head holder. The scans are taken over a 6-hour period after injection of [123I]5-I-A-85380. An electrocardiogram, respiration, and blood pressure measures are taken before the tracer is injected, then 5 minutes after the injection, and again 30 to 60 minutes after the injection. Blood and urine samples are collected 5 to 6 hours after starting the scan. Participants are asked to urinate at least every 2 hours for 12 hours after injection of [123I]5-I-A-85380 to decrease radiation exposure.

연구 개요

상태

완전한

정황

상세 설명

Parkinson's disease (PD) is the second most common neurodegenerative disorder. PD is characterized primarily by motor impairment, but cognitive impairment is common and dementia may occur in up to 50% of patients. Cholinergic deficits have been widely demonstrated in PD patients with and without dementia. Cholinergic deficits are more profound in the setting of PD with dementia. The cholinergic system mediates aspects of learning and memory and deficits in cholinergic function are correlated with the degree of dementia in PD. Additionally, the cholinergic system may mediate certain aspects of motor function in PD. Data on cholinergic function, particularly relating to nicotinic cholinergic receptors, are limited to post mortem studies, and little is known about the role of the cholinergic system in vivo and how it relates to clinical phenomena. The aim of the current study is to assess the feasibility and usefulness of imaging of the high affinity alpha 4 beta 2 nicotinic cholinergic receptor in vivo, using SPECT (single photon emission computed tomography) imaging in patients with PD. The long-term goal of the present study is to further understanding of the role of the cholinergic system in the pathogenesis of PD and to elucidate potential diagnostic and therapeutic targets.

연구 유형

관찰

등록

60

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Maryland
      • Bethesda, Maryland, 미국, 20892
        • National Institute of Neurological Disorders and Stroke (NINDS)

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이
  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

INCLUSION CRITERIA -Patients:

Age greater than or equal to 40.

Diagnosis of PD.

Consent.

Responsible Caregiver (only for patients with dementia).

INCLUSION CRITERIA - Controls:

Age greater than or equal to 40.

Consent.

EXCLUSION CRITERIA - Patients and Controls:

Secondary cause of Parkinsonism, e.g. Wilson's disease, neuroleptic use.

Dementia not due to PD, abnormal screening labs for dementia

Or severe dementia with MMSE less than 15.

Neurological disorder other than PD that would effect protocol (e.g. stroke, Alzheimer's disease).

Use of cholinergic or anticholinergic agents within 60 days.

Abnormal MRI other than mild atrophy.

Claustrophobia.

Pregnancy or breast feeding.

Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual limits.

Any conditions that increase risk for MRI (pacemaker, metallic foreign body, etc.).

Any medical condition that in the opinion of the investigators would, interfere with the safe conduct of the study.

Both healthy subjects and patients will be excluded if they have more than moderate hypertension. The subject may be on anti-hypertensive medications. The initial screening must show no more than moderate hypertension- i.e. less than 160/95. On baseline evaluation on the day of the scan (i.e., before injection of tracer), the subject must be asymptomatic (no headache, dizziness, neurological symptoms, or blurred vision) AND have sustained BP less than 180/100.

History of smoking tobacco, use of nicotine gum or patch or other uses of nicotine within last 5 years.

Inability to provide consent.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2003년 4월 1일

연구 완료

2005년 1월 1일

연구 등록 날짜

최초 제출

2003년 4월 11일

QC 기준을 충족하는 최초 제출

2003년 4월 10일

처음 게시됨 (추정)

2003년 4월 11일

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

2008년 3월 4일

QC 기준을 충족하는 마지막 업데이트 제출

2008년 3월 3일

마지막으로 확인됨

2005년 1월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다